AbCellera Biologics Earnings Call Transcripts
Fiscal Year 2026
-
The company has transitioned from a partnership-driven model to advancing its own pipeline, with a focus on challenging antibody targets and a strong liquidity position. Lead asset ABCL635 targets hot flashes in menopausal women, with key phase II data expected in Q3 and potential expansion into oncology-related indications.
-
A robust antibody-based drug discovery platform supports a growing pipeline, with lead asset ABCL635 in phase II targeting menopausal hot flashes and potential expansion to cancer therapy-induced symptoms. In-house manufacturing and strong financial backing enable flexibility and sustained development.
-
The company has evolved into a biotech with robust antibody discovery and manufacturing capabilities, advancing a pipeline led by ABCL635 for menopausal VMS, which is differentiated by safety and dosing convenience. Phase II data for ABCL635 is expected in Q3, with rapid expansion into oncology and additional assets progressing toward clinical trials.
-
The company has transitioned to a clinical-stage model, advancing a robust pipeline led by ABCL635 for menopause symptoms, with key data readouts expected in 2025. Strong liquidity, a new GMP facility, and a focus on differentiated, high-need indications position it for late-stage clinical expansion.
Fiscal Year 2025
-
Transitioned to a clinical-stage biotech, expanded pipeline to four clinical/IND-enabling programs, and ended 2025 with $700M liquidity. Revenue rose to $75M, net loss narrowed to $146M, and key clinical readouts are expected in 2026.
-
Transitioning to a clinical-stage biotech, the company now prioritizes internal drug development, highlighted by advanced programs in menopause and atopic dermatitis. Strong liquidity and end-to-end capabilities support a robust pipeline, with over 20 assets in development.
-
The company has completed its transition to developing proprietary clinical assets, with two wholly owned drugs in the clinic and a third in IND-enabling studies. ABCL635 targets a large unmet need in menopausal hot flashes, with proof-of-concept data expected in 2025. Liquidity exceeds CAD 700 million, supporting at least three years of operations.
-
Transitioned to a clinical-stage biotech with two phase I trials underway and strong liquidity of $680M. Revenue rose to $9M, but net loss widened to $57M as R&D investment increased. Confident in advancing pipeline and maintaining funding for over three years.
-
The company has shifted from a partnership and royalty model to advancing its own pipeline, with two proprietary antibodies now in clinical trials and more in development. Strong execution, robust financials, and differentiated assets targeting large unmet needs position it for future growth.
-
Q2 2025 saw major clinical milestones with two programs entering phase I trials and a third advancing to IND-enabling studies. Revenue rose sharply due to a one-time licensing fee, while liquidity remains strong at $750 million. Initial clinical data for lead assets is expected in mid-2026.
-
Transitioning to a clinical-stage biotech, two lead molecules are entering phase 1 trials in Q3, targeting large unmet needs in VMS and atopic dermatitis. Differentiation is driven by safety, dosing convenience, and a robust pipeline, with key data expected in H1 2026.
-
Advanced two lead programs toward phase I trials, with ABCL635 targeting menopause-related VMS and ABCL575 aiming for extended dosing in dermatology. Ended the quarter with $810 million in liquidity, reported a $46 million net loss, and continued investing in manufacturing and pipeline expansion.
-
Biotech innovation is accelerating, with a focus on building a sustainable, fully integrated antibody pipeline. Two new molecules are entering phase I trials, supported by strong cash reserves and a new GMP facility, while strategic partnerships and scientific differentiation remain key priorities.
-
The company is advancing two internal antibody programs toward clinical trials, with ABCL 575 targeting atopic dermatitis and ABCL 635 addressing a $2B+ market as the first biologic for its target. Manufacturing capabilities are coming online, and a validated T-cell engager platform has attracted a major partnership with AbbVie.
-
Plans include advancing two programs per year, with full vertical integration by 2025 and a focus on T-cell engagers and complex membrane protein targets. AI integration accelerates discovery, and strong capital reserves support multi-year growth. Key clinical data and GMP manufacturing milestones are expected within 18 months.
-
Significant partnerships and a shift to internal pipeline development mark a new phase, with two lead programs entering the clinic and robust liquidity supporting growth. Key catalysts include clinical trial initiations, data readouts in 2026, and ongoing T-cell engager platform progress.
Fiscal Year 2024
-
Transitioned to a clinical-stage biotech, advancing two lead programs toward clinical trials in 2025 and reducing new partnerships. Ended 2024 with $650M in cash and $840M in total liquidity, despite a net loss of $163M. Focus remains on pipeline growth and operational efficiency.
-
A decade of platform investment enables a shift to high-value internal antibody programs, with two IND filings planned next year. Lead assets target large markets with strong differentiation, while partnerships with major pharma and venture-backed collaborations expand opportunities. Robust TCE data and active partnering discussions highlight future growth.
-
A decade of technology building has enabled a shift from partnerships to an internal pipeline, with two lead antibody programs set for clinical entry next year and key data in 2026. The platform's integration and technical edge target challenging, high-value opportunities.
-
Transitioning to a fully integrated biotech, the company is leveraging its proprietary antibody discovery platform and manufacturing capabilities to advance a diversified internal pipeline. Two assets are set for Phase 1 trials in Canada, with strong liquidity supporting future growth.
-
Transitioned to a clinical-stage biotech with two lead programs on track for CTA filings in 2025 and a robust discovery pipeline. Ended Q3 with $670M in cash, reported a $51M net loss (including a $32M impairment), and expects stable R&D expenses into 2025.
-
The company is advancing its antibody discovery platform, expanding strategic partnerships, and shifting focus to internal pipeline growth, with two programs entering the clinic next year. Strong liquidity supports manufacturing expansion and ongoing R&D, aiming for sustainable growth and industry leadership.
-
The company is advancing a robust antibody discovery platform, validated by major pharma partnerships and a growing royalty portfolio, while shifting focus to internal pipeline development. Two lead programs are set for IND in 2025, supported by strong liquidity and integrated manufacturing capabilities.
-
Q2 2024 saw continued investment in internal pipeline and platform capabilities, with revenue declining to $7M and a net loss of $37M as focus shifted from partner research fees to internal programs. Strategic partnerships expanded, and liquidity remains strong at nearly $700M.
-
The company has transitioned from a technology platform to a clinical-stage biotech, leveraging strong liquidity and COVID-19-driven revenue to advance a robust internal pipeline. Key assets include an OX40L antagonist for atopic dermatitis and a first-in-class metabolic disorder therapy, both supported by government funding. AI and strategic partnerships remain central to innovation and growth.